Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Parabolic Drugs (PDL) has received an official accreditation from Japan's ministry of Health, Labour and Welfare, enabling it to manufacture and supply Cephalosporin non sterile drugs to the Japanese market. The 5-year accreditation has been awarded to PDL's manufacturing site at Derabassi in Punjab and is in accordance with article 13-3 of the Pharmaceutical Affairs Act, which classifies Parabolic Drugs as a certified foreign drug manufacturer.
Japan, the second single largest drug market in the world is also a leading nation in terms of pharma research, technology, machinery and medical research and is valued at $107 billion in 2010. The Japanese certification denotes the company's technical capability in the non-sterile market and also differentiates it from many of its competitors.
The EU GMP accredited Derabassi facility is a dedicated Cephalosporin manufacturing site that is spread across 27 acres and has an annual capacity over 900 tons of Cephalosporin. This accreditation is an essential element of company's regulatory market vision as the Japanese market is an arena it hopes to heighten its market presence.
The company sees an opportunity in building its regulated market business in the $21 billion global Cephalosporin molecule market and has over 38 DMFs filed across EU, Canada and USA. It also has over 3 molecules in pipeline for filing it in Japan. The company's exports accounted for 36.98% of the total revenues in FY11, with direct exports alone accounting to 28.21%.
Parabolic Drugs is Chandigarh based contract manufacturer of active pharmaceutical ingredients (APIs). Currently, it has six units at Sundhran, Derabassi, for manufacturing the oral and sterile range of Cephalosporin APIs and intermediates.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.85 |
| Dr. Reddys Lab | 5812.50 |
| Cipla | 1403.90 |
| Zydus Lifesciences | 1104.45 |
| Lupin | 1661.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
